Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03650023
Other study ID # RCK_OFTT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 9, 2018
Est. completion date July 25, 2018

Study information

Verified date August 2018
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is well known that Chitosan oligosaccharide is low molecular weight and water soluble and chitosan oligosaccharide has been shown to reduce blood cholesterol and blood pressure, increase immunity, and enhance antitumor properties. the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with normal blood glucose, impaired fasting glucose and impaired glucose tolerance.


Description:

A randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of chitosan oligosaccharide (GO2KA1). forty healthy male and female subjects aged 20-75 years with normal blood glucose, impaired fasting glucose and impaired glucose tolerance were recruited. The subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. On the screening visit, the participants were the 2-hr oral glucose tolerance test (OGTT) was conducted. And they were separated normal blood glucose, impaired fasting glucose and impaired glucose tolerance. On the first visit, the participants were randomly assigned to consume a test or placebo product [test product: chitosan oligosaccharide powder 500mg (GO2KA1); placebo product: white egg powder 500mg] and ingested the assigned product. On the second visit, the participants consumed the other product that they did not eat on the first visit. On both visit day, the 2-hr oral sucrose tolerance test (OSTT) was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (0.5, 1 and 2 hr) of the products.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date July 25, 2018
Est. primary completion date July 25, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 74 Years
Eligibility Inclusion Criteria:

- Normal Blood Glucose (fasting blood sugar below 100mg/dl, two hours after meals below 140mg/dl)

- Impaired Fasting Glucose (fasting blood sugar 100-125mg/dl)

- Impaired Glucose Tolerance (two hours after meals 140-199mg/dl)

Exclusion Criteria:

- history/presence of diabetes mellitus (including oral hypoglycaemic agent and insulin)

- history of serious hypoglycemia

- history of serious cardiovascular, cerebrovascular disease, pulmonary, gastrointestinal, hepatic, renal and/or haematological disease

- uncontrolled blood pressure (blood pressure level more than 140/90mmHg)

- history/presence of alcoholism, drug addiction, etc.

- taking a regulation of blood glucose medications within 1 month before study

- participation other intervention studies within 1 months before study

- history of diagnosed with cancer, cancer surgery and hospitalization

- women who are pregnant or desire to become pregnant during the study period

- having any other medical condition which, in the opinion of the investigator, could interfere with participation in the study

Study Design


Intervention

Dietary Supplement:
Chitosan Oligosaccharide (GO2KA1)
Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
White egg
White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.

Locations

Country Name City State
Korea, Republic of Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University. Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose levels Glucose level differences during the 2-hr oral sucrose tolerance test between White egg and chitosan oligosaccharide (GO2KA1) intak 2 hours
Secondary The areas under the curve (AUC) of glucose Glucose AUC differences between White egg and chitosan oligosaccharide (GO2KA1) intake 1 day of second visit (after finishing cross-over trial)
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Completed NCT02621060 - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance Phase 2
Completed NCT01488279 - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy N/A
Completed NCT01521312 - ACute and Chronic Effects of Saxagliptin Phase 2
Completed NCT01559896 - Egg Protein Hydrolysate and Vascular Function N/A
Completed NCT01030978 - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program N/A
Completed NCT00573781 - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism Phase 2
Terminated NCT00846521 - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity Phase 4
Completed NCT00241072 - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Phase 4
Completed NCT00536250 - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth N/A
Completed NCT02254317 - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance N/A
Completed NCT03764423 - Health Effects of Salmon Fishmeal in Humans N/A
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Active, not recruiting NCT04341571 - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes. Phase 2
Completed NCT02700334 - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Phase 4
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Completed NCT02135172 - Breaks in Sedentary Time and Glucose Regulation in Women N/A
Active, not recruiting NCT01841229 - Effect of Ginseng on Glycemic Control N/A
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A